OBIO
Orchestra BioMed Holdings, Inc. NASDAQ Listed Aug 4, 2020$6.25
After hrs
$6.25
+0.00%
Mkt Cap $240.0B
52w Low $2.35
100.0% of range
52w High $6.25
50d MA $4.72
200d MA $4.33
P/E (TTM)
-6.3x
EV/EBITDA
—
P/B
3676.5x
Debt/Equity
0.0x
ROE
-52.8%
P/FCF
-4852.3x
RSI (14)
71.10
ATR (14)
$0.41
Beta
0.60
50d MA
$4.72
200d MA
$4.33
Avg Volume
390.8K
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
150 Union Square Drive · New Hope, PA 18938 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BMO | -0.39 | -0.38 | +3.1% | 4.24 | +0.2% | +5.2% | -1.3% | +0.5% | +0.7% | -0.9% | — |
| May 12, 2026 | BMO | -0.40 | -0.33 | +17.5% | 3.91 | -0.3% | +3.8% | +0.0% | +1.2% | -9.5% | +7.0% | — |
| May 8, 2026 | BMO | — | — | — | 3.93 | +1.5% | +2.8% | -3.2% | +3.8% | +0.0% | +1.2% | — |
| Mar 12, 2026 | BMO | -0.38 | 0.26 | +168.4% | 4.38 | +0.0% | -4.1% | +8.3% | +1.3% | -2.2% | +2.9% | — |
| Nov 10, 2025 | BMO | -0.38 | -0.40 | -5.3% | 3.78 | -0.8% | +8.5% | +7.8% | -5.4% | -5.7% | +4.8% | — |
| Aug 12, 2025 | BMO | -0.51 | -0.50 | +2.0% | 2.72 | -0.7% | -2.2% | +0.0% | -3.4% | +2.3% | -3.0% | — |
| Apr 2, 2025 | BMO | -0.43 | -0.43 | +0.0% | 3.52 | -8.8% | -11.6% | -11.3% | +2.5% | -1.4% | +5.0% | — |
| Mar 26, 2025 | BMO | -0.43 | -0.37 | +14.0% | 4.38 | +4.1% | +5.0% | -4.3% | -2.7% | -24.3% | +8.6% | — |
| Nov 12, 2024 | BMO | -0.44 | -0.41 | +6.8% | 5.66 | +5.8% | +7.2% | +2.3% | -6.0% | -0.2% | -11.3% | — |
| Aug 12, 2024 | BMO | -0.41 | -0.45 | -9.8% | 6.11 | +2.3% | -2.5% | -7.0% | +9.4% | +5.9% | -0.5% | — |
| May 13, 2024 | BMO | -0.40 | -0.38 | +5.0% | 4.60 | +0.0% | +13.0% | -7.5% | -4.0% | +12.8% | +0.4% | — |
| Mar 27, 2024 | BMO | -0.38 | -0.37 | +2.6% | 5.31 | -1.3% | -0.8% | -6.1% | +1.8% | -2.8% | +1.4% | — |
| Nov 13, 2023 | BMO | -0.39 | -0.38 | +2.6% | 6.04 | -4.0% | +13.1% | +4.2% | -2.0% | -2.7% | -0.7% | — |
| Aug 10, 2023 | BMO | -0.42 | -0.35 | +16.7% | 6.07 | +1.6% | -1.6% | -1.7% | -3.9% | -5.3% | +2.4% | — |
| May 12, 2023 | AMC | -0.28 | -0.40 | -42.9% | 17.00 | +2.8% | +2.5% | -2.8% | +15.6% | -19.0% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 | BTIG Research | Upgrade | Neutral → Buy | $10 | $5.45 | $5.85 | +7.3% | +6.6% | +5.3% | -3.6% | +2.4% | -0.5% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $4.60 | $4.61 | +0.2% | -4.8% | -4.1% | +8.3% | +1.3% | -2.2% |
| Jan 9 | Barclays | Maintains | Overweight → Overweight | — | $4.84 | $4.96 | +2.5% | -0.8% | -2.9% | -8.2% | +4.2% | -6.5% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $4.42 | $4.38 | -0.9% | -5.4% | -5.7% | +4.8% | +2.4% | +10.2% |
| Nov 12 | Barclays | Maintains | Overweight → Overweight | — | $4.10 | $4.17 | +1.7% | +7.8% | -5.4% | -5.7% | +4.8% | +2.4% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.73 | +0.4% | +0.7% | +0.4% | -0.7% | -0.7% | -3.7% |
| Aug 20 | BTIG | Downgrade | Buy → Neutral | — | $2.55 | $2.56 | +0.4% | -4.7% | +2.5% | +2.4% | +2.0% | +15.4% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.72 | $2.70 | -0.7% | -2.2% | +0.0% | -3.4% | +2.3% | -3.0% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.64 | $2.68 | +1.5% | -1.5% | +4.2% | -7.0% | +7.9% | -2.2% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $2.65 | $2.72 | +2.6% | +10.9% | -4.1% | +2.5% | +0.3% | +0.7% |
| May 5 | Barclays | Maintains | Overweight → Overweight | — | $2.74 | $2.66 | -2.9% | -6.6% | -5.5% | +1.7% | +16.7% | -7.7% |
| Apr 22 | Chardan Capital | Maintains | Buy → Buy | — | $2.84 | $3.13 | +10.2% | +0.7% | -0.3% | -9.5% | +7.8% | -6.1% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.11 | $2.96 | -4.8% | -11.3% | +2.5% | -1.4% | +5.0% | -11.3% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $4.28 | $3.86 | -9.8% | -24.3% | +8.6% | -11.6% | -11.3% | +2.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.23 | $4.16 | -1.7% | -6.1% | +0.8% | +0.5% | -4.5% | +6.2% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.21 | $6.25 | +0.6% | -6.0% | -0.2% | -11.3% | +2.1% | +3.0% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $5.66 | $5.99 | +5.8% | +7.2% | +2.3% | -6.0% | -0.2% | -11.3% |
| Jun 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.96 | $8.14 | +2.3% | -0.3% | -1.5% | +1.9% | +0.9% | -7.5% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $5.31 | $5.24 | -1.3% | -0.8% | -6.1% | +1.8% | -2.8% | +1.4% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $6.07 | $6.17 | +1.6% | -1.6% | -1.7% | -3.9% | -5.3% | +2.4% |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | $5.54 | $5.79 | +4.5% | +2.3% | +7.1% | -1.6% | -1.7% | -3.9% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $17.00 | $17.47 | +2.8% | +2.5% | -2.8% | +15.6% | -19.0% | -4.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Hochman David PDir/Off | See Remarks | Buy | 10,000 | $4.79 | $48K | 1,070,746 | +0.37% | +2.37% |
| Sep 1, 2026 | Sherman DarrenDir/Off | See Remarks | Sell | 15,000 | $4.94 | $74K | 1,134,402 | -4.24% | +6.61% |
| Aug 26, 2026 | Sherman DarrenDir/Off | See Remarks | Buy | 2,000 | $5.33 | $11K | 2,000 | -2.89% | +7.17% |
| Aug 3, 2026 | Sherman DarrenDir/Off | See Remarks | Sell | 15,000 | $4.09 | $61K | 1,154,327 | -1.17% | -1.35% |
| Jul 1, 2026 | Sherman DarrenDir/Off | See Remarks | Sell | 15,000 | $4.27 | $64K | 1,169,327 | -2.63% | +1.79% |
| Jun 1, 2026 | Sherman DarrenDir/Off | See Remarks | Sell | 15,000 | $3.87 | $58K | 1,184,327 | -1.28% | +2.03% |
| Jun 1, 2026 | Hochman David PDir/Off | See Remarks | Buy | 5,000 | $3.83 | $19K | 1,064,029 | -1.28% | +2.03% |
| May 18, 2026 | Aryeh JasonDir | — | Buy | 665 | $3.75 | $2K | 118,118 | +3.02% | +0.76% |
| May 15, 2026 | Aryeh JasonDir | — | Buy | 8,971 | $3.90 | $35K | 117,453 | -0.50% | -0.50% |
| May 15, 2026 | Hochman David PDir/Off | See Remarks | Buy | 5,000 | $3.77 | $19K | 1,059,029 | -0.50% | -0.50% |
| May 14, 2026 | Fain Eric SDir | — | Buy | 20,000 | $4.13 | $83K | 91,709 | +0.50% | -2.22% |
| Apr 27, 2026 | RTW INVESTMENTS, LP | — | Sell | 32 | $4.13 | $132 | 9,556,063 | +5.00% | +2.49% |
8-K · 7.01
! Medium
Orchestra BioMed Holdings, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sep 8
8-K
Orchestra BioMed Holdings, Inc. -- 8-K Filing
Orchestra BioMed's executive compensation structure ties 2026 bonuses to both standard performance goals and challenging stretch goals, with potential upward adjustments if ambitious targets are exceeded.
Feb 13
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 8,306,063 | $35M | — | Mar 2026 |
| 2 | Blackrock, Inc. | 2,510,387 | $11M | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 2,022,916 | $9M | Reduced | Jun 2026 |
| 4 | Alyeska Investment Group, L.p. | 1,000,000 | $4M | — | Mar 2026 |
| 5 | Propel Bio Management, Llc | 896,701 | $4M | New | Mar 2026 |
| 6 | Vanguard Portfolio Management Llc | 274,973 | $1M | New | Jun 2026 |
| 7 | Knott David M Jr | 253,651 | $1M | — | Jun 2026 |
| 8 | Marshall Wace, Llp | 188,484 | $801K | Added | Mar 2026 |
| 9 | Jane Street Group, Llc | 173,765 | $721K | Added | Dec 2025 |
| 10 | Morgan Stanley | 163,702 | $679K | Added | Dec 2025 |
| 11 | Northern Trust Corp | 118,274 | $503K | Added | Mar 2026 |
| 12 | Citadel Advisors Llc | 112,382 | $485K | Reduced | Jun 2026 |
| 13 | Qube Research & Technologies Ltd | 108,953 | $463K | Added | Mar 2026 |
| 14 | Susquehanna International Group, Llp | 97,521 | $414K | Reduced | Mar 2026 |
| 15 | Renaissance Technologies Llc | 90,000 | $388K | Added | Jun 2026 |
| 16 | Ifp Advisors, Inc | 89,608 | $387K | Reduced | Jun 2026 |
| 17 | Daytona Street Capital Llc | 96,398 | $379K | Added | Jun 2026 |
| 18 | Barclays Plc | 59,342 | $252K | Reduced | Mar 2026 |
| 19 | Nuveen, Llc | 52,118 | $225K | New | Jun 2026 |
| 20 | Bank Of America Corp /de/ | 52,761 | $224K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$239.95B
Enterprise Value
$239.85B
P/E (TTM)
-6.31x
Forward P/E
—
PEG Ratio
90.81x
P/B
3676.47x
P/S
7504.21x
P/FCF
-4852.27x
EV/EBITDA
—
Shares Out
38.39B
Financials (TTM)
Revenue
$32.0M
Net Income
-$59.0M
EBITDA
-$57.1M
Free Cash Flow
-$49.5M
Op Cash Flow
-$49.0M
EPS Basic
$-1.11
EPS Diluted
$-0.99
EPS Forward
$-1.77
Gross Margin
99.3%
Op Margin
-181.4%
Net Margin
-184.6%
Balance Sheet
Total Assets
$114.9M
Total Liab.
$51.5M
Total Equity
$63.4M
Cash
$106.5M
LT Debt
$936K
Book Value/Sh
$0.00
Debt/Equity
0.03x
Current Ratio
6.45
Quick Ratio
6.43
Returns & Growth
ROE
-52.8%
ROA
-45.9%
ROIC
-52.4%
Rev Growth YoY
+1169.2%
EPS Growth YoY
+33.1%
Price Returns
2W
+28.3%
1M
+9.5%
3M
+49.0%
6M
+31.0%
12M
+149.2%
Technicals
52W High
$6.25
52W Low
$2.35
50d MA
$4.72
200d MA
$4.33
RSI (14)
71.10
ATR (14)
$0.41
Beta
0.60
Avg Volume
391K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 26, 2026 4:46pm
· Source: financialmodelingprep.com